These drugs offer substantial potential health benefits, but the combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage.
The paradigm for treating people with obesity has often been to recommend lifestyle changes, and then if they develop diabetes or another metabolic condition, to treat them with metformin, insulin, or GLP-1 drugs, says study senior and corresponding author Andrew Stokes, associate professor of global health
A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity
Back Moody, AJ, Holst, JJ, Thim, L, Lindkaer Jensen, S (5 Feb 1981) 'Relationship of glicentin to proglucagon and glucagon in the porcine pancreas', Nature , 289, 514-16
The FDA has issued public communications addressing concerns associated with compounded semaglutide and tirzepatide products, including risks involving dosing errors, storage handling, adverse events, and misleading marketing claims
.jpg)
